Ashe Andrew D. 4
4 · Verve Therapeutics, Inc. · Filed Feb 16, 2024
Insider Transaction Report
Form 4
Ashe Andrew D.
See Remarks
Transactions
- Award
Restricted Stock Units
2024-02-14+36,000→ 36,000 total→ Common Stock (36,000 underlying) - Award
Stock Option (right to buy)
2024-02-14+150,000→ 150,000 totalExercise: $12.75Exp: 2034-02-13→ Common Stock (150,000 underlying)
Footnotes (3)
- [F1]The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.
- [F2]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F3]On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.